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MaOBJECTIVES The goal of this study was to assess the real-world clinical utility of fractional ﬂow reserve (FFR) derived
from coronary computed tomography angiography (FFRCT) for decision-making in patients with stable coronary artery
disease (CAD).
BACKGROUND FFRCT has shown promising results in identifying lesion-speciﬁc ischemia. The real-world feasibility and
inﬂuence on the diagnostic work-up of FFRCT testing in patients suspected of having CAD are unknown.
METHODS We reviewed the complete diagnostic work-up of nonemergent patients referred for coronary computed
tomography angiography over a 12-month period at Aarhus University Hospital, Denmark, including all patients with
new-onset chest pain with no known CAD and with intermediate-range coronary lesions (lumen reduction, 30% to 70%)
referred for FFRCT. The study evaluated the consequences on downstream diagnostic testing, the agreement between
FFRCT and invasively measured FFR or instantaneous wave-free ratio (iFR), and the short-term clinical outcome after
FFRCT testing.
RESULTS Among 1,248 patients referred for computed tomography angiography, 189 patients (mean age 59 years;
59% male) were referred for FFRCT, with a conclusive FFRCT result obtained in 185 (98%). FFRCT was #0.80 in 31% of
patients and 10% of vessels. After FFRCT testing, invasive angiography was performed in 29%, with FFR measured in 19%
and iFR in 1% of patients (with a tendency toward declining FFR-iFR guidance during the study period). FFRCT #0.80
correctly classiﬁed 73% (27 of 37) of patients and 70% (37 of 53) of vessels using FFR #0.80 or iFR #0.90 as the
reference standard. In patients with FFRCT >0.80 being deferred from invasive coronary angiography, no adverse cardiac
events occurred during a median follow-up period of 12 (range 6 to 18 months) months.
CONCLUSIONS FFRCT testing is feasible in real-world symptomatic patients with intermediate-range stenosis
determined by coronary computed tomography angiography. Implementation of FFRCT for clinical decision-making may
inﬂuence the downstream diagnostic workﬂow of patients. Patients with an FFRCT value >0.80 being deferred from
invasive coronary angiography have a favorable short-term prognosis. (J Am Coll Cardiol Img 2016;-:-–-) © 2016 by
the American College of Cardiology Foundation.m the aDepartment of Cardiology, Aarhus University Hospital Skejby, Aarhus, Denmark; bDepartment of Radiology, St. Paul’s
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ABBR EV I A T I ON S
AND ACRONYMS
CABG = coronary artery bypass
grafting
CAD = coronary artery disease
CTA = computed tomography
angiography
FFR = fractional ﬂow reserve
FFRCT = coronary computed
tomography angiography–
derived fractional ﬂow reserve
ICA = invasive coronary
angiography
iFR = instantaneous wave-free
ratio
LAD = left anterior descending
artery
LCx = left circumﬂex artery
MPI = myocardial perfusion
imaging
RCA = right coronary artery
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2C urrent guidelines recommendnoninvasive functional imagingtesting as the ﬁrst-line strategy in
patients with suspected stable coronary
artery disease (CAD) (1). However, shortcom-
ings of current noninvasive diagnostic strate-
gies are apparent from the frequent
inaccurate selection of patients for invasive
coronary angiography (ICA) (2). Randomized
trials have shown that a fractional ﬂow
reserve (FFR) threshold of 0.80 distinguishes
patients and lesions that will (3–5) and will
not (4–6) beneﬁt from coronary revasculari-
zation. FFR has therefore emerged as the
reference standard for guiding coronary
revascularization in intermediate-range le-
sions (7,8). Noninvasive anatomic assess-
ment using coronary computed tomography
angiography (CTA) reveals high diagnostic
performance for detection or exclusion of
CAD. However, coronary CTA tends to over-estimate obstructive CAD, and the correlation of ste-
noses to downstream myocardial ischemia is poor
(9). Consequently, guidelines recommend additional
stress testing in ambiguously symptomatic patients
with suspected obstructive CAD determined by coro-
nary CTA (1).
Recent advances in computational ﬂuid dynamics
and individual image-based modeling permit calcu-
lation of coronary blood ﬂow and pressure from
standard acquired coronary CTA datasets (10–12). This
technique allows for noninvasive calculation of FFR
(coronary computed tomography angiography–
derived fractional ﬂow reserve [FFRCT]). In 3 pro-
spective multicenter trials that included 609 patients
(1,050 vessels) with known or suspected CAD and
blinded comparison to FFR, FFRCT exhibited a high
and superior diagnostic performance compared
with stenosis assessment according to coronary CTA
(10–12). However, because of the potential selection
bias in these studies, concerns have been raised
regarding to what extent FFRCT in stable CAD can be
translated into clinical practice (13,14). We report
the ﬁrst real-world experience of coronary CTA with
FFRCT as gatekeeper to the catheterization labora-
tory in nonemergent symptomatic patients with
intermediate-range coronary lesions.
METHODS
This single-center, observational all-comers study
was conducted in symptomatic patients with
suspected CAD referred to coronary CTA at Aarhus
University Hospital between May 1, 2014, andApril 30, 2015. In this institution, coronary CTA
testing is the preferred initial diagnostic modality in
patients with new-onset chest pain with no known
CAD and low-intermediate pre-test probability of
disease (1). Patients were referred to nonemergent
ambulatory coronary CTA from our outpatient clinic,
2 community hospitals, and 2 private cardiologist
practices. Before performance of the coronary CTA,
all patients underwent 12-lead electrocardiogram
and routine biochemistry, echocardiography, and
clinical evaluation by a cardiovascular physician;
noninvasive ischemia testing (using exercise elec-
trocardiography) was performed only in patients
being referred from private cardiologist practices.
Demographic and clinical characteristics, data on
downstream diagnostic testing, and clinical follow-
up were obtained from patient ﬁles and registries
(15). The study was approved by the Danish Data
Protection Agency (1-16-02-414-15) with a waiver for
individual informed consent by the regional ethical
committee.
CORONARY CTA ACQUISITION, ANALYSIS, AND
DIAGNOSTIC CONSEQUENCE. Coronary CTA was
performed using a dual-source CT scanner (SOMA-
TOM Deﬁnition Flash; Siemens, Forchheim, Ger-
many). Contraindications were renal insufﬁciency,
pregnancy, or allergy to contrast. Image acquisition
was performed in accordance with society guidelines
(16). Oral and/or intravenous beta-blockers or oral
ivabradine were administered if necessary, targeting
a heart rate <60 beats/min, and all patients received
sublingual nitrates. An initial nonenhanced scan for
calcium scoring was performed using high-pitch spi-
ral acquisition mode and 120 kV. Coronary CTA was
performed using prospective electrocardiographic
triggering in all patients. In the event of a heart
rate #65 beats/min or >65 beats/min, the recom-
mended RR scan intervals were 65% to 75% and 40%
to 70%, respectively. Data acquisition was performed
with 100- or 120-kV tube voltage in patients
weighing #70 or >70 kg. Filtered back-projection
was used for image reconstruction. Scans were
assessed by using axial images and multiplanar
reconstructions by experienced cardiologists. Vessel
segments $2 mm were evaluated for lumen narrow-
ing, and the per-vessel maximum stenosis category
(30% to 50%, 51% to 70%, 71% to 90%, and >90%) was
reported. The strategy of stenosis quantiﬁcation was
at the discretion of the CT scan interpreter. The car-
diologists reading the CT scans grouped patients into
1 of 3 risk categories on the basis of the coronary
anatomy (1); recommendations regarding down-
stream patient management were based on these
TABLE 1 Local Recommendations of Downstream Diagnostic
Work-Up of Patients After Coronary CTA and FFRCT Testing
Between May 2014 and April 2015
Test Outcome
Downstream
Diagnostic Test
Coronary CTA
High risk* ICA
Diagnostic conclusive Intermediate risk† FFRCT
Low risk‡ No additional testing§
Diagnostic inconclusive — Myocardial perfusion
imaging
FFRCT #0.80 ICA
>0.80 No additional testing§
*Patients with left main, 3-vessel disease, and/or high-grade proximal left anterior
descending artery stenosis. †Patients with 1 or 2 intermediate coronary stenoses
(lumen reduction 30% to 70%). ‡Patients with no coronary disease or with
maximum coronary stenosis <30%. §Optimal medical treatment was recom-
mended. If coronary artery disease was present, statin, aspirin, and/or antianginal
medication were generally prescribed or recommended via the general
practitioner.
CTA ¼ computed tomography angiography; FFRCT ¼ coronary computed to-
mography angiography–derived fractional ﬂow reserve; ICA ¼ invasive coronary
angiography.
FIGURE 1 Patient Example
A 51-year-old man presented with new-onset atypical chest pain. (A) Coronary computed
tomography angiography (curved multiplanar reconstructions) showed 50% to 70% ste-
noses (pink arrows) in the left anterior descending (LAD) (A1), circumﬂex (LCx) (A2), and
right coronary (RCA) (A3) arteries, respectively. (B) Coronary computed tomography
angiography–derived fractional ﬂow reserve (FFRCT) indicated that lesions were not he-
modynamically signiﬁcant. (C) Invasive coronary angiography demonstrated 2 50% to
60% stenoses (yellow arrows) in the (C1) LCx and the (C2) RCA, and mild luminal irreg-
ularities in LAD. FFRCT values in LCx and RCA were 0.92 and 0.88, respectively; distally
measured FFR in the LAD was 0.88.
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3categories (Table 1). Subsequent myocardial perfusion
imaging (MPI) with rest-stress 82-rubidium positron
emission tomography was recommended in patients
in whom the coronary CTA interpreter deemed the
result as inconclusive.
FFRCT ANALYSIS. A standard coronary CTA dataset
was transmitted for analysis (HeartFlow, Inc., Red-
wood City, California) (12). Clinical information
related to FFRCT analysis was restricted to patient
weight, height, heart rate, and blood pressure. The
principles behind FFRCT computation have been
described previously (10–12). FFRCT was displayed for
each point in the coronary tree. FFRCT values distally
in the major epicardial (left main, left anterior
descending [LAD], left circumﬂex [LCx], and right
coronary [RCA]) arteries (including side branches)
>2 mm in diameter were registered. FFRCT #0.80 was
considered diagnostic of lesion-speciﬁc ischemia
(10–12). Recommendations during the study period on
downstream patient management according to the
FFRCT result are shown in Table 1. Figure 1 displays a
representative case.
FOLLOW-UP. The proportion of patients having ICA
performed as a consequence of the FFRCT result was
registered. The proportion of patients having subse-
quent coronary revascularization (percutaneous cor-
onary intervention [PCI] or coronary artery bypass
grafting [CABG]) was registered. Patients were fol-
lowed up for a median of 12 (range 6 to 18 months)
months during which the occurrence of cardiac
events (death, acute myocardial infarction, and
angina leading to hospital admission or visit in theoutpatient clinic) and diagnostic procedures (ICA,
coronary CTA, and MPI) were recorded. No patients
were lost to follow-up.
ICA AND FFR. ICA and FFR were performed accord-
ing to standard practice by experienced invasive
cardiologists. All information relevant for patient
management, including the FFRCT result, was avail-
able for decision-making. Decisions on measuring
FFR and coronary revascularization were at the
discretion of the interventionalist. Measurement of
FFR was performed using the PressureWire (St. Jude
Medical, St. Paul, Minnesota) or the ComboWire XT
guidewire (Volcano Therapeutics, Cordova, Califor-
nia). The pressure sensor was advanced past the most
distal stenosis, and FFR was measured during intra-
venous infusion of adenosine (140 to 180 mg/kg/min)
via the antecubital vein. Intracoronary nitroglycerin
(100 to 250 mg) was given before introduction of the
FFR guidewire. Instantaneous wave-free ratio (iFR)
FIGURE 2 Work-Up of Patients Referred to Coronary CTA Between May 2014 and April 2015
Referred to coronary CTA
N = 1248
MPI 
n = 32
OMT
n = 10
- Contrast
n = 75
MPI
n = 44
FFRCT 
n = 189
+ Contrast
n = 1173
ICA
n = 82
OMT*
n = 858
ICA 
n = 33
*Of the 858 patients discharged from the outpatient clinic without further testing, 270 (31%) had cholesterol-lowering medication, aspirin,
and/or antianginal medication prescribed. CTA ¼ computed tomography angiography; FFRCT ¼ coronary computed tomography angiography–
derived fractional ﬂow reserve; ICA ¼ invasive coronary angiography; MPI ¼ myocardial perfusion imaging; OMT ¼ optimal medical treatment.
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4was measured in few patients (17). FFR #0.80 or
iFR #0.90 was indicative of ischemia.
RADIATION EXPOSURE. Cumulative radiation expo-
sure including all diagnostic tests are reported in
millisieverts using the formula mSv ¼ (dose length
product)  0.014 for coronary CTA, a conversion fac-
tor of 0.18 mSv/(Gy cm2) for ICA (18), and 0.00126
MBq/mSv for MPI (19).
STATISTICAL ANALYSIS. Categorical data are pre-
sented as numbers or proportions. Continuous data
are presented as mean  SD, median (interquartile
range), or median (range) as appropriate. Fisher’s
exact test, chi-squared test, Mann-Whitney U test, or
the Student t test were used for comparisons as
appropriate. Correlation of per-vessel FFRCT to FFR
was assessed using the Pearson correlation coefﬁcient
and Bland-Altman analysis. Statistical analyses were
performed using Stata version 14.0 (Stata Corp, Col-
lege Station, Texas).
RESULTS
Figure 2 displays the diagnostic ﬂow of patients
referred for coronary CTA during the study period.
Contrast was not administered in 75 patients because
of irregular heart rhythm and/or severe coronary
calciﬁcation and/or inadequate patient cooperation.
In this patient group, 77% were in sinus rhythm; the
mean heart rate was 72 (range 53 to 131 beats/min)
beats/min; and the median Agatston score was 617
(interquartile range: 56 to 2,024; range 0 to 4,723).
Because of inconclusive coronary CTA results(low contrast, severe motion, misalignment, and/or
blooming artifacts), 33 (3%) patients were referred for
subsequent MPI. In 11 (1%) patients with a conclusive
coronary CTA result and $1 intermediate lesion, MPI
was the preferred downstream test strategy. Baseline
characteristics of patients in whom coronary CTA was
performed are shown in Table 2. Before coronary CTA
testing, exercise electrocardiography was performed
in 12% of the patients without temporal changes in
proportions during the study. Baseline characteristics
of patients referred directly to ICA based on the cor-
onary CTA result or to MPI are shown in Table 3. No
proportional changes during the study period in
direct referrals to ICA or MPI could be detected.
FFRCT. Table 3 presents the baseline characteristics of
patients scheduled for FFRCT testing. A conclusive
FFRCT result was available within 24 h in 185 (98%)
patients. In 4 patients, FFRCT computation was not
possible due to calcium blooming, motion, and/or low
contrast (n ¼ 3) or missing diastole reconstruction for
myocardial segmentation (n ¼ 1). The per-patient and
per-vessel distribution of FFRCT values are shown in
Figure 3. In 31% (57 of 185) of patients and 10% (72 of
740) of vessels, FFRCT was #0.80. Among these 185
patients, intermediate stenoses were present in 303
vessels (left main, n ¼ 9; LAD, n ¼ 156; LCx, n ¼ 62;
RCA, n ¼ 76). FFRCT in these vessels was 0.85  0.08
(range 0.43 to 0.98) versus 0.92  0.05 (range 0.78 to
1.00) in vessels without stenosis or with <30% ste-
nosis (p < 0.0001). In the latter group, FFRCT
was #0.80 (range 0.78 to 0.80) in 5 (1%) vessels (LCx,
n ¼ 4; RCA, n ¼ 1).
TABLE 3 Baseline Characteristics of Patients Referred to FFRCT,
Invasive Coronary Angiography, or Myocardial Perfusion Imaging Testing
on the Basis of Coronary CTA Outcome
ICA*
(n ¼ 82)
FFRCT†
(n ¼ 189)
MPI‡
(n ¼ 44)
Age, yrs 58  10, 37–78 59  9, 34–78 61  9, 42–78
Male 51 (62) 111 (59) 24 (55)
Diabetes 10 (12) 24 (13) 7 (16)
Hypertension 36 (44) 82 (43) 19 (43)
Hyperlipidemia 32 (39) 73 (39) 18 (41)
Current smoker 18 (22) 43 (23) 11 (25)
Family history of CAD 41 (50) 96 (51) 24 (55)
Symptoms
Typical angina 46 (56) 29 (15)§ 6 (14)
Atypical angina 32 (39) 117 (62)§ 28 (64)
Nonanginal chest pain 1 (1) 17 (9)§ 6 (14)
Dyspnea 3 (4) 26 (14)§ 4 (9)
Updated Diamond-Forrester
risk score, %
53 41§ 40
Intermediate (20%–80%)
pre-test risk
72 (88) 162 (86) 38 (86)
Noninvasive ischemia
testing performed
before coronary CTA
14 (17) 19 (10) 3 (7)
Body mass index, kg/m2 28  3 26  4 26  4
Serum creatinine, mmol/l 79  19 77  16 73  16
Heart rate, beats/min 60  13, 41–122 58  8, 40–93 59  9, 41–87
Sinus rhythm 78 (95) 189 (100)§ 42 (95)k
Agatston score 79 (16–259; 0–4,830) 61 (9–209; 0–1,277)§ 89 (6–268; 0–1,390)
Maximum coronary CTA
stenosis severity¶
30%–49% 22 (18) 110 (36)§ 0§
50%–69% 49 (41) 165 (54)§ 10 (83)§
70%–89% 49 (41) 28 (9)§ 2 (17)
>90% 0 (0) 0 (0) 0 (0)
Cumulative radiation
exposure, mSvk
8.8  6.6 3.2  1.1§ 7.0  1.2§
Values are mean  SD, range, n (%), % or median (IQR; range). *Patients with high-risk anatomy (i.e., left main,
3-vessel disease, and/or high-grade proximal left anterior descending artery stenosis) preferably were referred
for ICA. †FFRCT testing was recommended in patients with 1 or 2 intermediate coronary stenosis (lumen reduction
30% to 70%). ‡MPI was performed due to an inconclusive coronary CTA result (n ¼ 33) or because of the
presence of intermediate stenosis (n ¼ 11). §Indicates p < 0.05 compared with the group on its left. kFor ICA and
MPI, the radiation dose associated with the preceding coronary CTA examination is included. Both the non-
contrast and contrast-enhanced CT scans are included in the estimate. ¶A total of 303 vessels were tested in the
FFRCT assessment group, 120 vessels in the ICA group, and 12 vessels in the MPI group.
MPI ¼ myocardial perfusion imaging; other abbreviations as in Tables 1 and 2.
TABLE 2 Baseline Characteristics of Patients in Whom Coronary
CTA was Performed
Coronary CTA
(n ¼ 1,173)
Age, yrs 57  11, 25–85
Male 551 (47)
Diabetes 117 (10)
Hypertension 399 (34)
Hyperlipidemia 340 (29)
Current smoker 205 (17)
Family history of CAD 538 (46)
Symptoms
Typical angina 152 (13)
Atypical angina 763 (65)
Nonanginal chest pain 176 (15)
Dyspnea 82 (7)
Updated Diamond-Forrester risk score, % 34
Intermediate (20%–80%) pre-test risk 844 (72)
Noninvasive ischemia testing
performed before coronary CTA
141 (12)
Body mass index, kg/m2 26  4
Serum creatinine, mmol/l 74  15
Heart rate, beats/min 58  9, 37–122
Sinus rhythm 1,152 (98)
Agatston score 0 (0–54; 0–4,830)
Effective CT radiation dose, mean  SD 3.2  1.4*
Values are mean  SD, range, n (%), %, or median (IQR; range). *Includes both the
noncontrast and contrast-enhanced scan.
CAD ¼ coronary artery disease; CT ¼ computed tomography; CTA ¼ computed
tomography angiography; IQR ¼ interquartile range.
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5The diagnostic work-up of patients after FFRCT
testing is shown in Figure 4. Median time between CT
scan and catheterization was 30 (range 1 to 121) days.
In 37 patients, FFR (n ¼ 35) or iFR interrogation was
performed. The proportion of patients having FFR or
iFR measured in the ﬁrst two-thirds versus the last
one-third of the study period was 77% (27 of 35) and
53% (10 of 19), respectively (p ¼ 0.08). FFR was
measured in 51 vessels and iFR in 2 vessels (LAD, n ¼
34; LCx, n ¼ 8; RCA, n ¼ 11).
There was good direct correlation of per-vessel
FFRCT to FFR, with a slight systematic underestima-
tion of FFRCT compared with FFR (Figure 5). Overall,
FFRCT #0.80 correctly classiﬁed 73% (27 of 37) of
patients and 70% (37 of 53) of vessels by using
FFR #0.80 or iFR #0.90 as the reference standard.
There was an inverse continuous relationship be-
tween the FFRCT numerical value and the probability
of detecting ischemia (Table 4). The diagnostic
agreement of FFRCT #0.80 according to coronary
stenosis severity using FFR or iFR as the reference
standard, as well as median (interquartile range;
range) FFRCT in vessels with “true or false-positive”
or “true or false-negative” FFRCT test results are
shown in Table 5. FFRCT values in 3 “false-negative”vessels ranged between 0.81 and 0.83, all with a
corresponding FFR value of 0.79. On a patient level,
no FFRCT “false-negative” outcomes were observed.
CORONARY REVASCULARIZATION AND FOLLOW-UP. In
patients with FFRCT #0.80 being referred to ICA,
45% (22 of 49) underwent coronary revascularization
(PCI, n ¼ 12; CABG, n ¼ 10). In 23 patients with
FFRCT #0.75 being referred to ICA (FFR or iFR
measured, n ¼ 13), revascularization was performed
in 70% (PCI, n ¼ 10; CABG, n ¼ 6). In patients referred
from coronary CTA directly to ICA, FFR or iFR was
measured in 20% without temporal proportional
changes during the study, and 65% (53 of 82)
FIGURE 3 Distribution of FFRCT Values
(A) Per-patient minimum coronary computed tomography angiography–derived fractional
ﬂow reserve (FFRCT) values (n ¼ 185). (B) Total per-vessel FFRCT (n ¼ 740) values and
values in vessels giving rise to FFRCT analysis (n ¼ 303) (red).
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6underwent revascularization (PCI, n ¼ 42; CABG, n ¼
11). No patients having FFRCT, ICA, or MPI performed
experienced a serious adverse cardiac event during
follow-up, including the 123 (66%) patients with
FFRCT >0.80 in whom ICA was deferred. In 1 patient
with the lowest FFRCT value of 0.88 (LAD) and 1 pa-
tient with FFRCT ¼ 0.78 (LAD) in whom ICA originally
was deferred, subsequent ICAs were performed after
4 and 6 months of follow-up, respectively, because of
continuing chest pain. ICA revealed minor vessel ir-
regularities (no FFR interrogation) in the former pa-
tient, and diffuse nonobstructive disease (measured
FFR ¼ 0.84) in the other patient. In the MPI group,
ICA was performed in 2 patients during follow-up
(normal test results).
DISCUSSION
This report demonstrates for the ﬁrst time the real-
world feasibility of FFRCT testing in consecutive
patients with intermediate-range coronary stenosis.
We made several important observations: 1) conclu-
sive FFRCT results were obtained in 98% of patients
who had CT scans referred for FFRCT testing; 2)
implementation of FFRCT for clinical decision-
making may inﬂuence the downstream diagnostic
workﬂow; 3) in the event of FFRCT #0.75, the risk of
a false-positive result using FFR as the referencestandard is very low (<10%), whereas in patients
with FFRCT ranging between 0.76 and 0.80, a non-
negligible number of false-positive results may be
expected; and 4) patients with FFRCT >0.80 being
deferred from ICA have a favorable short-term
prognosis.
In the most recent trial (NXT [Analysis of Coronary
Blood Flow Using CT Angiography: Next Steps])
investigating the diagnostic performance of FFRCT in
stable CAD, 13% of the patients had nonevaluable
coronary CTA images (12). In this real-world report,
we found that only 2% of patients failed to meet the
image quality requirements for FFRCT analysis. Tak-
ing into account those patients in whom contrast
was not administered because of an anticipated
nondiagnostic CT image quality and those with
an inconclusive test outcome, a conclusive CT
scan–based anatomic or anatomic-physiological
result was available in >90% of all patients referred
to coronary CTA testing. These ﬁndings most likely
reﬂect that CT image acquisition in this report was
performed in accordance with guidelines, with care-
ful attention to heart rate control and use of nitro-
glycerin (16,20). Of note, it was recently shown that
FFRCT also provides high and superior diagnostic
performance compared with coronary CTA alone in
patients with high calcium scores (21). This outcome,
together with future improvements in CT spatial
resolution, may expand the eligibility of coronary
CTA to patients in whom a nondiagnostic CT image
quality is anticipated and to those with an inconclu-
sive test result due to severe coronary calciﬁcation.
Accordingly, MPI may potentially be avoided in a
substantial proportion of patients in the diagnostic
pathway of coronary CTA.
The recent multicenter PLATFORM (Prospective
Longitudinal Trial of FFRCT: Outcome and Resource
Impacts) trial demonstrated, in patients referred to
ICA, that a diagnostic strategy of coronary CTA and
FFRCT resulted in safe cancellation of planned ICAs
in 61% of the patients (22). Similarly, in the present
study that includes a contemporary coronary CTA
cohort, a “normal” FFRCT result was present in 69%
of the patients, among whom ICA was successfully
deferred. On the other hand, the coronary revascu-
larization rate in patients with FFRCT #0.80 in this
study was surprisingly low (45%). This ﬁnding is
partially explained by the high proportion of false-
positive results in patents with FFRCT between 0.75
and 0.80. Accordingly, the revascularization rate
increased to 70% in patients with FFRCT #0.75.
Moreover, decisions on revascularization, especially
in the FFR range between 0.75 and 0.80, are often
inﬂuenced by factors other than FFR (e.g., severity
FIGURE 4 Diagnostic Work-Up of Patients After FFRCT Testing
FFRCT
n = 185
+ ICA
n = 5
> 0.80
n = 128
- ICA
n = 123
≤ 0.80
n = 57
+ ICA
n = 49
- ICA
n = 8
FFR
n = 4
FFR or iFR
n = 33
Instantaneous wave-free ratio (iFR) was measured in 2 patients. In patients referred for ICA
(n ¼ 54), fractional ﬂow reserve (FFR) was not measured in 19 patients (angiographic
minor changes, n ¼ 9; high-grade stenosis, n ¼ 5; technical reasons, n ¼ 3; contraindication
to adenosine, in which case iFR was performed, n ¼ 2). Mean (range) FFRCT in vessels with
minor angiographic changes or high-grade stenosis were 0.79 (0.74 to 0.84) and 0.63
(0.43 to 0.77), respectively. In 4 patients with FFRCT >0.80, measured FFR mirrored the
FFRCT results. Abbreviations as in Figure 2.
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7of angina) (4,5). Finally, it should be acknowledged
that “thresholds” by individual CT operators in
prescribing subsequent FFRCT testing govern the
proportion of normal and abnormal results. In
the present study, this decision was recommended
primarily on the basis of coronary anatomy; how-
ever, integration to a varying degree of other
factors (including preference of downstream testing
modality and information on pre-test risk of CAD
and symptoms) naturally may have inﬂuenced
decision-making regarding downstream patient
management.
The high negative predictive value of FFRCT for the
prediction of ischemia (10–12), as well as the ﬁndings
in the PLATFORM trial (22) and in this report of a
favorable short-term clinical outcome in patients with
FFRCT >0.80, may encourage conﬁdence for clini-
cians that such patients can safely be deferred for
subsequent ICA. However, in the NXT trial, using an
FFRCT dichotomous interpretation approach, despite
diagnostic superiority compared with coronary CTA
stenosis assessment alone, the FFRCT per-patient
speciﬁcity and positive predictive value in predict-
ing ischemia were modest (79% and 65%, respec-
tively) (12). Thus, a substantial rate of false-positive
results remained. After our initial clinical experiences
with FFRCT testing as described in this report, our
institution recently implemented an FFRCT testing
decision-rule algorithm (Figure 6). We recommend in
patients with FFRCT ranging between 0.75 and 0.80
that decisions on referral to ICA should be based on
all available information, in particular regarding the
severity of angina (i.e., the main target of PCI),
whereas in patients with FFRCT >0.80 or #0.75, we
propose a dichotomous interpretation strategy.
Several factors support the relevance of this
approach. First, in accordance with this report, the
overall prognosis in patients with stable chest pain in
contemporary practice is favorable (22,23), and the
annual risk of cardiac death or myocardial infarction
after deferral of coronary revascularization in
intermediate-range lesions with FFR $0.75 is very
low (<1%) (6). Moreover, it should be acknowledged
that FFR exhibits a continuous relationship between
its numerical value and the clinical outcome, with the
largest beneﬁt of revascularization being obtained at
lower FFR values (5). In this study, the lower limit of
FFRCT values among patients with a false-positive
result was modestly low (0.74), and, in the event of
FFRCT #0.75, the probability of having ischemia was
high (92%), whereas if FFRCT ranged between 0.76
and 0.80, ischemia was present in only 55% of the
patients. Accordingly, it has been shown that the
variation in repeated FFR (24) measurements andFFRCT calculations (25) has the largest impact on
interpretation of results when approaching the
established cutpoint of 0.80. The ﬁnding in this study
and in previous studies of a slight systematic under-
estimation of FFRCT compared with measured FFR
(10–12) support the proposed FFRCT guidance algo-
rithm. Safety and cost-efﬁciency of this FFRCT guid-
ance diagnostic workﬂow in symptomatic patients
with intermediate-range coronary lesions need
delineation in future studies.
We observed a higher proportion of FFR guidance
(69% vs. 20%) and lower revascularization rate (45%
vs. 65%) in patients being referred to ICA based on
FFRCT assessment compared with patients being
referred directly from coronary CTA. These ﬁndings
may reﬂect the higher severity in risk, symptoms, and
CAD in the latter group, thus encouraging direct PCI
in the majority of patients. In addition, the extensive
use of FFR testing in patients being referred to ICA
based on the FFRCT result may reﬂect an FFRCT
diagnostic uncertainty among the interventionalists,
thus prompting “reassurance” FFR measurements.
FIGURE 5 Correlation and Bland-Altman Plots of FFR and FFRCT in Vessels Having FFR Measured (n ¼ 51)
BA
0.6 0.7 0.8 0.9 1.0
FFRCT
FF
R
1.0
0.9
0.8
0.7
0.6
r = 0.77
p <0.001
0.6 0.7 0.8 0.9 1.0
(FFR + FFRCT)/2
FF
R
-F
FR
CT
Bias±SD: 0.04±0.05 (p<0.001)
95% Limits of agreement: -0.06, 0.14
0.2
0.1
0.0
-0.1
-0.2
Green represents 2 overlying data points and red represents 3 overlying data points. Abbreviations as in Figures 3 and 4.
TABLE 4 Per-Patient and Per-Vessel Agreement for Detection
of Ischemia According to FFRCT at Different Thresholds #0.80
Patients
(n ¼ 33)
Vessels
(n ¼ 37)
#0.80 70 (23/33) 65 (24/37)
0.76–0.80* 55 (11/20) 50 (11/22)
0.71–0.75* 83 (5/6)† 75 (6/8)†
#0.70* 100 (7/7)† 100 (7/7)†
Values are % (n/N). Fractional ﬂow reserve #0.80 was used as reference. *When
comparing per-patient and per-vessel agreement estimates between the lower 3
FFRCT range categories, p values were 0.06 and 0.04, respectively. †Two patients
(vessels) in whom instantaneous wave-free ratio #0.90 was used as the reference
standard.
FFRCT ¼ coronary computed tomography angiography–derived fractional ﬂow
reserve.
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8This scenario is supported by the observation that
FFR guidance in this group was reduced by 30%
during the study period. Finally, in accordance with
previous trials and real-world observations (3–5,26),
the lower revascularization rate in this group may
at least partially reﬂect the more extensive use ofTABLE 5 Per-Vessel FFRCT Test Outcome According to Coronary Sten
True Positive Fals
Coronary stenosis severity
30%–50% 4 (22)
51%–70% 15 (56) 8
71%–90% 5 (63)* 2
FFRCT 0.74 (0.69–0.78; 0.65–0.80) 0.78 (0.76–0
Values are n (%) or median (IQR; range). FFRCT #0.80 was diagnostic of ischemia. Refer
ratio #0.90 (n ¼ 2) was used as reference. †Range (IQR) not shown because of low nu
Abbreviations as in Tables 1 and 2.FFR testing per se. It can be speculated that the
implementation of FFRCT and the extensive use of
FFR in patients referred to ICA after FFRCT testing
may stimulate the overall institutional adoption of
FFR. However, in this study, FFR guidance in patients
being referred directly from coronary CTA to ICA was
relatively infrequent throughout the study period.
We cannot exclude that the use of uncaptured PCI
guidance procedures such as intravascular ultrasound
and optical coherence tomography may have inﬂu-
enced the PCI operators’ overall threshold for FFR
testing (26).
STUDY LIMITATIONS. This study was a single-center,
observational trial with inherent limitations. Data
were collected in a nonselected cohort of patients and
involved multiple CT and PCI operators unblinded to
the FFRCT results. However, it included all patients
encountered in a deﬁned time period and represents
consecutive data from a relevant study cohort in a
real-world setting. FFRCT–FFR agreement estimates
were based on few observations and most likely wereosis Severity
e Positive True Negative False Negative
3 (17) 10 (56) 1 (6)
(30) 2 (7) 2 (7)
(25) 1 (13) 0
.80; 0.74–0.80) 0.88 (0.84–0.88; 0.81–0.90) 0.81 (0.81–0.83)†
ence standard was fractional ﬂow reserve #0.80 (n ¼ 51). *Instantaneous wave-free
mber of observations.
FIGURE 6 The “Aarhus” FFRCT Decision-Rule Algorithm
Coronary CTA*
FFRCT
≤ 0.75 0.76 - 0.80 > 0.80
+ Symptoms - Symptoms
Intermediate risk anatomy† Low risk anatomy†High risk anatomy†
3-months follow-up
OMT OMTICA
*Patients with new-onset chest pain without known coronary artery disease, low to intermediate pre-test probability of disease, and in whom a
diagnostic coronary CTA result can be expected. †”High risk anatomy” is deﬁned as the presence of left main, 3-vessel and/or high-grade left
anterior descending artery stenosis; “intermediate risk anatomy” as 1 or 2 intermediate stenoses (30% to 70%); and “low risk anatomy” as
normal or stenosis <30%. Abbreviations as in Figures 2 and 4.
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9inﬂuenced by selection bias. However, measurement
of FFR in more low- or high-grade lesions may have
resulted in higher agreement estimates (27). No cur-
rent guidelines provide recommendations about the
clinical use of FFRCT testing and its interpretation.
Thus, in this study, FFRCT testing was recommended
in patients with intermediate-range lesions in whom
coronary CTA interpretation is most challenging and
for whom guidelines recommend performance of
additional ischemia testing (1). We did not consider
the reduction in angina. However, during 12 months
of follow-up, the rate of symptom-driven ICA was
low. No information on the downstream primary
physician contact was obtainable, leaving questions
about changes in medication unanswered. The
implementation of a “standard diagnostic testing”
comparison group and a longer follow-up period
would have added valuable information. Patients
with emergent chest pain were not included in this
study. FFRCT testing requires offsite computer pro-
cessing, with a current 3- to 6-h turnaround time. A
reduced order model for on-site (<1 h) CT scan–basedderivation of FFR, which may be relevant in the acute
setting, was recently introduced (28). However,
further investigations in prospective multicenter tri-
als are needed to determine the diagnostic perfor-
mance of this technique.
CONCLUSIONS
FFRCT testing is feasible in real-world patients with
intermediate-range coronary stenosis determined by
coronary CTA. Implementation of FFRCT for clinical
decision-making may inﬂuence the downstream
diagnostic workﬂow of patients. Patients with
FFRCT >0.80 being deferred from ICA have a
favorable short-term prognosis. We propose an
“FFRCT guidance algorithm” to be evaluated in
future studies.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Bjarne L. Nørgaard, Department of Cardiology,
Aarhus University Hospital Skejby, Skejby DK-8200
Aarhus N, Denmark. E-mail: bnorgaard@dadlnet.dk.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: FFRCT is
feasible in real-world symptomatic patients with
intermediate-range coronary stenosis. Real-world imple-
mentation of FFRCT for clinical decision-making may in-
ﬂuence the downstream diagnostic workﬂow of patients.
Patients being deferred from ICA based on an FFRCT value
>0.80 have a favorable short-term prognosis.
TRANSLATIONAL OUTLOOK: FFRCT is a promising
gatekeeper to the catheterization laboratory in patients
with intermediate-range coronary stenosis. In this sce-
nario, future studies are needed to evaluate the safety and
cost-efﬁciency of FFRCT relative to conventional nonin-
vasive ischemia-testing modalities. We propose an “FFRCT
guidance algorithm” to be evaluated in future studies.
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